Bruker (BRKR) Stock Forecast, Price Target & Predictions
BRKR Stock Forecast
Bruker stock forecast is as follows: an average price target of $73.75 (represents a 31.18% upside from BRKR’s last price of $56.22) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
BRKR Price Target
The average price target for Bruker (BRKR) is $73.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $60.00. This represents a potential 31.18% upside from BRKR's last price of $56.22.
BRKR Analyst Ratings
According to 7 Wall Street analysts, Bruker's rating consensus is 'Buy'. The analyst rating breakdown for BRKR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bruker Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Patrick Donnelly | Citigroup | $80.00 | $67.54 | 18.45% | 42.30% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $78.00 | $63.95 | 21.97% | 38.74% |
| May 20, 2024 | Daniel Arias | Stifel Nicolaus | $77.00 | $76.47 | 0.69% | 36.96% |
| May 05, 2021 | Tycho Peterson | J.P. Morgan | $60.00 | $68.86 | -12.87% | 6.72% |
The latest Bruker stock forecast, released on Sep 23, 2024 by Patrick Donnelly from Citigroup, set a price target of $80.00, which represents a 18.45% increase from the stock price at the time of the forecast ($67.54), and a 42.30% increase from BRKR last price ($56.22).
Bruker Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $79.00 | $78.33 |
| Last Closing Price | $56.22 | $56.22 | $56.22 |
| Upside/Downside | -100.00% | 40.52% | 39.33% |
In the current month, the average price target of Bruker stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bruker's last price of $56.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | Barclays | - | Overweight | Initialise |
| Sep 30, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
| Sep 23, 2024 | Citigroup | Buy | Buy | Hold |
| Aug 28, 2024 | Wells Fargo | Overweight | Positive | Initialise |
| Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
| Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Jul 10, 2024 | Citigroup | Buy | Buy | Hold |
| May 20, 2024 | Citigroup | Buy | Buy | Hold |
| May 20, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Feb 15, 2024 | UBS | Buy | Buy | Hold |
Bruker's last stock rating was published by Barclays on Oct 15, 2024. The company Initialise its BRKR rating from "null" to "Overweight".
Bruker Financial Forecast
Bruker Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $854.50M | $742.80M | $681.90M | $685.30M | $708.40M | $638.90M | $588.40M | $595.00M | $683.50M | $608.90M | $570.80M | $554.70M | $627.50M | $511.40M | $424.60M | $424.00M | $599.90M | $521.10M |
| Avg Forecast | $1.08B | $958.50M | $917.10M | $883.80M | $1.01B | $909.32M | $854.26M | $822.62M | $963.28M | $866.46M | $799.47M | $729.88M | $807.45M | $714.61M | $647.82M | $639.76M | $680.10M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| High Forecast | $1.10B | $980.42M | $938.07M | $904.01M | $1.04B | $930.11M | $873.79M | $834.70M | $997.68M | $867.09M | $799.47M | $746.57M | $807.66M | $727.78M | $662.64M | $654.39M | $695.66M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| Low Forecast | $1.06B | $946.31M | $905.44M | $872.56M | $1.00B | $897.75M | $843.39M | $811.92M | $953.63M | $865.83M | $799.47M | $720.59M | $807.22M | $703.69M | $639.58M | $631.62M | $671.45M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 7 | 3 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.05% | 1.07% | 1.04% | 1.05% | 1.00% | 1.04% | 1.03% | 1.06% | 1.06% | 1.08% | 1.04% | 1.05% | 1.08% | 0.96% | 1.04% | 1.05% |
Bruker's average Quarter revenue forecast for Mar 24 based on 1 analysts is $729.88M, with a low forecast of $720.59M, and a high forecast of $746.57M. BRKR's average Quarter revenue forecast represents a -14.58% decrease compared to the company's last Quarter revenue of $854.50M (Dec 23).
Bruker EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 7 | 3 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $144.90M | $160.50M | $117.50M | $153.10M | $161.40M | $155.30M | $108.00M | $125.70M | $143.90M | $137.20M | $114.60M | $115.80M | $147.40M | $104.80M | $56.80M | $36.00M | $136.90M | $99.60M |
| Avg Forecast | $208.57M | $185.53M | $177.52M | $171.07M | $196.07M | $176.01M | $165.35M | $159.23M | $186.46M | $167.72M | $154.75M | $130.69M | $156.29M | $138.32M | $125.40M | $118.80M | $162.91M | $121.43M | $117.10M | $93.92M | $131.77M | $114.50M | $106.92M | $66.56M | $120.11M | $96.53M | $77.93M | $47.72M | $114.84M | $98.37M |
| High Forecast | $213.34M | $189.77M | $181.58M | $174.98M | $200.56M | $180.04M | $169.14M | $161.57M | $193.12M | $167.84M | $154.75M | $156.82M | $156.33M | $140.87M | $128.26M | $142.57M | $195.49M | $121.43M | $117.10M | $112.70M | $131.77M | $114.50M | $106.92M | $79.88M | $120.11M | $96.53M | $77.93M | $57.27M | $114.84M | $98.37M |
| Low Forecast | $205.91M | $183.17M | $175.26M | $168.90M | $193.58M | $173.77M | $163.25M | $157.16M | $184.59M | $167.59M | $154.75M | $104.55M | $156.25M | $136.21M | $123.80M | $95.04M | $130.33M | $121.43M | $117.10M | $75.13M | $131.77M | $114.50M | $106.92M | $53.25M | $120.11M | $96.53M | $77.93M | $38.18M | $114.84M | $98.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.16% | 0.94% | 1.29% | 0.99% | 1.28% | 0.92% | 1.34% | 1.09% | 1.20% | 1.07% | 1.74% | 1.23% | 1.09% | 0.73% | 0.75% | 1.19% | 1.01% |
1 analysts predict BRKR's average Quarter EBITDA for Mar 24 to be $130.69M, with a high of $156.82M and a low of $104.55M. This is -9.81% lower than Bruker's previous annual EBITDA (Dec 23) of $144.90M.
Bruker Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 7 | 3 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $205.50M | $88.10M | $57.10M | $76.50M | $97.40M | $88.10M | $49.50M | $61.60M | $76.00M | $87.10M | $57.60M | $56.70M | $68.90M | $54.30M | $24.10M | $10.50M | $68.60M | $61.30M |
| Avg Forecast | $141.90M | $119.54M | $112.19M | $104.01M | $135.39M | $103.56M | $86.61M | $80.04M | $109.11M | $89.40M | $76.33M | $71.43M | $101.60M | $94.13M | $72.39M | $64.94M | $83.27M | $81.82M | $66.84M | $51.33M | $86.59M | $65.49M | $56.29M | $35.44M | $83.14M | $46.54M | $8.50M | $14.61M | $87.28M | $55.96M |
| High Forecast | $146.12M | $123.09M | $115.53M | $107.10M | $139.42M | $106.64M | $89.19M | $83.12M | $130.09M | $90.65M | $76.35M | $85.72M | $106.29M | $97.12M | $74.54M | $77.92M | $99.92M | $81.82M | $66.84M | $61.60M | $86.59M | $65.49M | $56.29M | $42.52M | $83.14M | $46.54M | $8.50M | $17.53M | $87.28M | $55.96M |
| Low Forecast | $139.56M | $117.56M | $110.34M | $102.29M | $133.15M | $101.85M | $85.18M | $76.97M | $102.11M | $88.14M | $76.31M | $57.14M | $96.91M | $92.64M | $71.19M | $51.95M | $66.62M | $81.82M | $66.84M | $41.07M | $86.59M | $65.49M | $56.29M | $28.35M | $83.14M | $46.54M | $8.50M | $11.69M | $87.28M | $55.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.02% | 0.94% | 0.79% | 1.18% | 1.17% | 1.08% | 0.74% | 1.20% | 0.88% | 1.33% | 1.02% | 1.60% | 0.83% | 1.17% | 2.83% | 0.72% | 0.79% | 1.10% |
Bruker's average Quarter net income forecast for Mar 24 is $71.43M, with a range of $57.14M to $85.72M. BRKR's average Quarter net income forecast represents a -65.24% decrease compared to the company's last Quarter net income of $205.50M (Dec 23).
Bruker SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 7 | 3 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $205.20M | $177.60M | $177.90M | $162.70M | $164.70M | $144.80M | $152.20M | $145.70M | $156.50M | $141.40M | $134.70M | $131.90M | $132.90M | $114.90M | $104.30M | $125.60M | $133.10M | $125.90M |
| Avg Forecast | $257.58M | $229.13M | $219.24M | $211.28M | $242.15M | $217.38M | $204.21M | $196.65M | $230.28M | $207.13M | $191.12M | $169.42M | $193.02M | $170.83M | $154.86M | $154.01M | $168.63M | $145.82M | $140.62M | $121.75M | $158.24M | $137.50M | $128.40M | $82.44M | $144.24M | $115.92M | $93.59M | $176.00M | $137.91M | $118.13M |
| High Forecast | $263.47M | $234.37M | $224.25M | $216.11M | $247.69M | $222.35M | $208.88M | $199.54M | $238.50M | $207.28M | $191.12M | $203.30M | $193.07M | $173.98M | $158.41M | $184.82M | $202.36M | $145.82M | $140.62M | $146.10M | $158.24M | $137.50M | $128.40M | $98.92M | $144.24M | $115.92M | $93.59M | $211.20M | $137.91M | $118.13M |
| Low Forecast | $254.31M | $226.22M | $216.45M | $208.59M | $239.07M | $214.61M | $201.62M | $194.09M | $227.97M | $206.98M | $191.12M | $135.53M | $192.97M | $168.22M | $152.90M | $123.21M | $134.90M | $145.82M | $140.62M | $97.40M | $158.24M | $137.50M | $128.40M | $65.95M | $144.24M | $115.92M | $93.59M | $140.80M | $137.91M | $118.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.15% | 1.06% | 0.98% | 0.99% | 1.08% | 1.20% | 0.99% | 1.03% | 1.05% | 1.60% | 0.92% | 0.99% | 1.11% | 0.71% | 0.97% | 1.07% |
Bruker's average Quarter SG&A projection for Mar 24 is $169.42M, based on 1 Wall Street analysts, with a range of $135.53M to $203.30M. The forecast indicates a -17.44% fall compared to BRKR last annual SG&A of $205.20M (Dec 23).
Bruker EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 7 | 3 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.41 | $0.60 | $0.39 | $0.52 | $0.66 | $0.60 | $0.33 | $0.41 | $0.50 | $0.58 | $0.38 | $0.37 | $0.45 | $0.35 | $0.16 | $0.07 | $0.45 | $0.40 |
| Avg Forecast | $0.95 | $0.80 | $0.75 | $0.70 | $0.91 | $0.70 | $0.58 | $0.54 | $0.73 | $0.60 | $0.51 | $0.47 | $0.68 | $0.63 | $0.49 | $0.55 | $0.72 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| High Forecast | $0.98 | $0.83 | $0.78 | $0.72 | $0.94 | $0.72 | $0.60 | $0.56 | $0.87 | $0.61 | $0.51 | $0.47 | $0.71 | $0.65 | $0.50 | $0.57 | $0.74 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| Low Forecast | $0.94 | $0.79 | $0.74 | $0.69 | $0.90 | $0.68 | $0.57 | $0.52 | $0.69 | $0.59 | $0.51 | $0.47 | $0.65 | $0.62 | $0.48 | $0.54 | $0.71 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.06% | 0.95% | 0.80% | 0.95% | 0.91% | 1.09% | 0.73% | 0.98% | 0.85% | 1.31% | 1.00% | 1.13% | 0.80% | 1.11% | 2.78% | 0.31% | 0.76% | 1.06% |
According to 1 Wall Street analysts, Bruker's projected average Quarter EPS for Mar 24 is $0.47, with a low estimate of $0.47 and a high estimate of $0.47. This represents a -67.01% decrease compared to BRKR previous annual EPS of $1.41 (Dec 23).
Bruker Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUNG | Pulmonx | $6.42 | $11.93 | 85.83% | Buy |
| IRTC | iRhythm | $73.90 | $121.17 | 63.96% | Buy |
| KIDS | OrthoPediatrics | $26.47 | $39.60 | 49.60% | Buy |
| BIO | Bio-Rad Laboratories | $325.58 | $482.50 | 48.20% | Buy |
| LIVN | LivaNova | $51.70 | $70.50 | 36.36% | Buy |
| CNMD | CONMED | $71.71 | $96.00 | 33.87% | Buy |
| BRKR | Bruker | $56.22 | $73.75 | 31.18% | Buy |
| OFIX | Orthofix Medical | $18.68 | $24.00 | 28.48% | - |
| ZBH | Zimmer Biomet | $108.40 | $133.78 | 23.41% | Hold |
| FNA | Paragon 28 | $10.43 | $11.50 | 10.26% | Buy |
| AORT | Artivion | $28.03 | $30.60 | 9.17% | Buy |
| ITGR | Integer | $135.88 | $138.00 | 1.56% | Buy |
| SRDX | Surmodics | $39.19 | $39.50 | 0.79% | Buy |
| GKOS | Glaukos | $140.83 | $123.44 | -12.35% | Buy |